Jérôme Denis

2 months ago | onlinelibrary.wiley.com | Vincent Guiraud |Hôpital Pitié-Salpêtrière |Jérôme Denis

Since the food and drug administration launched an investigation in late 2023 into cases of T-cell malignancies arising after chimeric antigen receptor (CAR) therapies,1 including CAR-positive lymphomas, several case reports have highlighted a CAR-specific oncogenesis risk, partially due to insertional mutagenesis.2, 3 This specific hazard arises directly from the dependence on viral vectors for CAR production, which allow persistent CAR expression through gene integration.